contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


intellego-enters-negotiations-with-global-pharma-group

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Intellego Technologies is a company active in photochromic indicator technology. The company supplies photochromic inks that design visual indicators that enable the effects of invisible ultraviolet light to be seen. The ink changes color based on exposure to ultraviolet radiation or specific substances. The products are primarily used by OEM manufacturers and are used in industry applications globally. Intellego Technologies was founded in 2011 and is headquartered in Stockholm.

Intellego Technologies

Intellego has initiated negotiations with one of the world’s largest companies in the pharmaceutical consumables and production sector. This US-based company has over 10,000 employees and operates...

<div class="mfn-preamble"><p><strong>Intellego has initiated negotiations with one of the world’s largest companies in the pharmaceutical consumables and production sector. This US-based company has over 10,000 employees and operates in more than 150 countries. It is a subsidiary of one of the world’s leading pharmaceutical groups, which employs over 80,000 people globally.</strong></p></div><div class="mfn-body"><p>The company has spent the past nine months evaluating Intellego’s UV LED dosimeters and the market, yielding positive results. The aim of this collaboration is to launch&nbsp;Intellego’s UV LED dosimeters, and potentially other dosimeter products, on the global&nbsp;market which has an estimated value of EUR 2 billion per year. </p><p>The launch is planned for 2025, with sales expected to increase progressively over time.</p></div><div class="mfn-footer mfn-contacts mfn-79847ae48c06"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p><strong>For further information, please contact:</strong><br>Claes Lindahl,&nbsp;CEO Intellego Technologies AB<br>E-mail: <a rel="noopener" href="mailto:claes.lindahl@intellego-technologies.com">claes.lindahl@intellego-technologies.com</a><br>Phone: +46&nbsp;735&nbsp;344 634</p></div><div class="mfn-footer mfn-about mfn-d6eb73c4bfb8"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>Intellego Technologies develops and manufactures color indicators that show the effect of irradiation with, among other things, invisible ultraviolet light, UV light. Color indicators are used globally in, for example, the disinfection industry, the sunscreen industry, and the manufacturing industry. Intellego's indicators have been developed from the company's patented photochromic ink, which can be adapted to different wavelengths of light and various application areas across a range of different industries. Intellego Technologies was founded in 2011, is headquartered in Stockholm, and is listed on the Nasdaq First North Growth Market.<br>The company's Certified Adviser on the Nasdaq First North Growth Market Stockholm is Carnegie Investment Bank AB (publ).</p><p>Intellego's website: <a rel="noopener" href="https://intellego-technologies.com/en/">https://intellego-technologies.com/en/</a></p><p>Subscribe to Intellego's press releases: <a rel="noopener" href="https://intellego-technologies.com/sv/pressmeddelanden/">https://intellego-technologies.com/sv/pressmeddelanden/</a></p><p>Contact the communications team: <a rel="noopener" href="mailto:communications@intellego-technologies.com">communications@intellego-technologies.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/bd029324-e1ad-4c19-ab8b-d67b5e1c2bbf/intellego-enters-negotiations-with-global-pharma-group.pdf" class="mfn-generated mfn-primary">Intellego enters negotiations with global pharma group</a></p></div>